Telix Pharmaceuticals to Outline Growth Strategy at Melbourne Capital Markets Day

  • Telix Pharmaceuticals will host a Capital Markets Day in Melbourne on November 4, 2026, from 9:00 a.m. to 12:30 p.m. AEDT.
  • The event will focus on updates to Telix's commercial portfolio, late-stage pipeline, and strategic growth opportunities.
  • Key opinion leaders will provide perspectives on Telix's theranostic programs alongside presentations from Telix leadership.
  • The event will be webcast live and available via the Investor Relations section of Telix's website.

Telix Pharmaceuticals is positioning itself as a leader in the theranostics space, leveraging its commercial diagnostics portfolio to drive growth. The Capital Markets Day comes at a critical juncture as the company advances its late-stage therapeutic pipeline, aiming to capitalize on the increasing demand for targeted cancer treatments. The event will provide key insights into Telix's strategic direction amidst a rapidly evolving radiopharmaceutical landscape.

Pipeline Progress
How the updates on TLX591-Tx, TLX101-Tx, and TLX250-Tx will impact investor confidence in Telix's late-stage pipeline.
Commercial Strategy
Whether Telix can sustain its commercial momentum with Illuccix, Gozellix, and Pixclara in an increasingly competitive radiopharmaceutical market.
Market Expansion
The pace at which Telix can expand its commercial footprint beyond the 22 countries where Illuccix is currently available.